{"generic":"Dolutegravir Sodium","drugs":["Dolutegravir Sodium","Tivicay"],"mono":{"0":{"id":"930754-s-0","title":"Generic Names","mono":"Dolutegravir Sodium"},"1":{"id":"930754-s-1","title":"Dosing and Indications","sub":[{"id":"930754-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>HIV infection:<\/b> Treatment-naive or treatment-experienced but integrase strand inhibitor-naive (INSTI-naive): 50 mg ORALLY once daily<\/li><li><b>HIV infection:<\/b> INSTI-experienced with certain known or suspected INSTI-associated resistance substitutions: 50 mg ORALLY twice daily<\/li><li><b>HIV infection:<\/b> Treatment-naive or treatment-experienced but INSTI-naive, when used in combination with the following potent UGT1A\/CYP3A inducers efavirenz, fosamprenavir\/ritonavir, tipranavir\/ritonavir, or rifampin: 50 mg ORALLY twice daily<\/li><\/ul>"},{"id":"930754-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in pediatric patients younger than 12 years or weighing less than 40 kg or who are integrase-strand inhibitor (INSTI)-experienced with known or suspected resistance to other INSTIs (ie, raltegravir or elvitegravir)<\/li><li><b>HIV infection:<\/b> (12 years or older and weighing at least 40 kg) Treatment-naive or treatment-experienced, integrase strand inhibitor-naive: 50 mg ORALLY once daily<\/li><li><b>HIV infection:<\/b> When used in combination with the following potent UGT1A\/CYP3A inducers efavirenz, fosamprenavir\/ritonavir, tipranavir\/ritonavir, or rifampin: 50 mg ORALLY twice daily<\/li><\/ul>"},{"id":"930754-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild to severe, treatment-naive, or treatment-experienced and integrase strand transfer inhibitor-naive:<\/b> no adjustment necessary<\/li><li><b>renal impairment, mild to moderate, integrase strand transfer inhibitor-experienced with known or suspected resistance:<\/b> no adjustment necessary<\/li><li><b>renal impairment, severe, integrase strand transfer inhibitor-experienced with known or suspected resistance:<\/b> caution advised<\/li><li><b>hepatic impairment, mild to moderate, Child-Pugh score A or B:<\/b> no adjustment necessary<\/li><li><b>hepatic impairment, severe, Child-Pugh score C:<\/b> use not recommended<\/li><li><b>concomitant use with a potent UGT1A\/CYP3A inducer (ie, efavirenz, fosamprenavir\/ritonavir, tipranavir\/ritonavir, or rifampin), treatment-naive, or treatment-experienced and integrase strand transfer inhibitor-naive:<\/b> 50 mg ORALLY twice daily<\/li><li><b>concomitant use with a potent UGT1A\/CYP3A inducer (ie, efavirenz, fosamprenavir\/ritonavir, tipranavir\/ritonavir, or rifampin), integrase strand transfer inhibitor-experience with known or suspected resistance:<\/b> use an antiretroviral regimen that does not include metabolic inducers or use alternatives to rifampin<\/li><li><b>concomitant use with calcium or iron-containing products:<\/b> administer dolutegravir either 2 hours before or 6 hours after<\/li><\/ul>"},{"id":"930754-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>HIV infection<br\/>"}]},"3":{"id":"930754-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930754-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant use with dofetilide<\/li><li>Hypersensitivity to dolutegravir<\/li><\/ul>"},{"id":"930754-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- Underlying hepatitis B or C at increased risk for new or worsening elevated transaminases (sometimes consistent with immune reconstitution syndrome or hepatitis B reactivation, particularly if anti-hepatitis therapy was withdrawn); monitoring recommended<\/li><li>-- Severe hepatic impairment (Child-Pugh score C); use not recommended<\/li><li>Immunologic:<\/li><li>-- Hypersensitivity reactions (characterized by rash, constitutional findings, and organ dysfunction, including liver injury) have been reported; discontinue use immediately if signs or symptoms develop<\/li><li>-- Immune reconstitution syndrome has been reported; inflammatory response to opportunistic infections (eg, Mycobacterium avium, cytomegalovirus, Pneumocystis jiroveci pneumonia, TB) may occur during initial phase of combination antiretroviral therapy<\/li><li>-- Autoimmune disorders, including Graves disease, polymyositis, and Guillain-Barr  syndrome, have been reported in the setting of immune reconstitution; may occur many months after initiation of therapy<\/li><li>Renal:<\/li><li>-- Use with caution in patients with severe renal impairment who are also integrase strand transfer inhibitor (INSTI) experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance; loss of therapeutic effect and development of resistance may occur due to decreased concentrations<\/li><li>Concomitant Use:<\/li><li>-- Etravirine without coadministration of atazanavir and ritonavir, darunavir and ritonavir, or lopinavir and ritonavir not recommended<\/li><li>-- Avoid nevirapine<\/li><li>-- Avoid metabolic inducers (oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St John's wort)<\/li><\/ul>"},{"id":"930754-s-3-11","title":"Pregnancy Category","mono":"Dolutegravir: B (FDA)<br\/>"},{"id":"930754-s-3-12","title":"Breast Feeding","mono":"Dolutegravir: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930754-s-4","title":"Drug Interactions","sub":[{"id":"930754-s-4-13","title":"Contraindicated","mono":"<ul>Dofetilide (probable)<\/ul>"},{"id":"930754-s-4-14","title":"Major","mono":"<ul><li>Apixaban (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (probable)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etravirine (established)<\/li><li>Fosamprenavir (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Metformin (probable)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxcarbazepine (probable)<\/li><li>Paritaprevir (theoretical)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Primidone (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>St John's Wort (probable)<\/li><li>Tipranavir (established)<\/li><\/ul>"},{"id":"930754-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum (established)<\/li><li>Calcium (established)<\/li><li>Iron (established)<\/li><li>Magaldrate (established)<\/li><li>Magnesium (established)<\/li><li>Sucralfate (established)<\/li><li>Zinc (established)<\/li><\/ul>"}]},"5":{"id":"930754-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hyperglycemia (grade 2 to 4, up to 12%)<\/li><li><b>Hepatic:<\/b>Increased serum lipase level (grade 3 to 4, 1% to 8%)<\/li><li><b>Neurologic:<\/b>Headache (moderate to severe, up to 2%), Insomnia (grade 1, 1% to 7%; grade 2 to 4, less than 1% to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hepatic:<\/b>ALT\/SGPT level raised (grade 2 to 4, up to 8%; hepatitis B and\/or C coinfection, 8% to 16% (grade 2 to 4)), AST\/SGOT level raised (grade 2 to 4, up to 6%), Hepatitis (less than 2%), Serum bilirubin raised (grade 2, up to 2%; grade 3, up to 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (up to 1%), Immune reconstitution syndrome<\/li><li><b>Renal:<\/b>Renal impairment (less than 2%)<\/li><\/ul>"},"6":{"id":"930754-s-6","title":"Drug Name Info","sub":{"0":{"id":"930754-s-6-17","title":"US Trade Names","mono":"Tivicay<br\/>"},"2":{"id":"930754-s-6-19","title":"Class","mono":"<ul><li>Antiretroviral Agent<\/li><li>Integrase Inhibitor<\/li><\/ul>"},"3":{"id":"930754-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930754-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930754-s-7","title":"Mechanism Of Action","mono":"Dolutegravir is an integrase strand transfer inhibitor that blocks retroviral DNA integration in the HIV replication cycle.<br\/>"},"8":{"id":"930754-s-8","title":"Pharmacokinetics","sub":[{"id":"930754-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 2 to 3 hours (single-dose); 5 days (steady-state)<\/li><li>Bioavailability, Oral: not established<\/li><li>Effects of food: Increased extent, decreased rate<\/li><\/ul>"},{"id":"930754-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 98.9% or greater<\/li><li>Vd: 17.4 L<\/li><\/ul>"},{"id":"930754-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: primary site via UGT1A1 with some contribution from CYP3A<\/li><li>ether glucuronidated dolutegravir (major): activity unknown<\/li><li>inhibitor of OCT2 renal organic cation transporter<\/li><li>substrate of UGT1A1, UGT1A3, UGT1A9, CYP3A, Breast Cancer Resistant Protein Transporter, and P-glycoprotein<\/li><\/ul>"},{"id":"930754-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 53% unchanged<\/li><li>Renal: 31% changed<\/li><li>Renal clearance: less than 1%<\/li><li>Dialyzable: No (hemodialysis, peritoneal dialysis)<\/li><li>Total body clearance: 1 L\/hr<\/li><\/ul>"},{"id":"930754-s-8-27","title":"Elimination Half Life","mono":"14 hours <br\/>"}]},"9":{"id":"930754-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may be taken with or without food<\/li><li>take 2 hours before or 6 hours after taking medications containing polyvalent cations (eg, magnesium, aluminum, iron or calcium)<\/li><\/ul>"},"10":{"id":"930754-s-10","title":"Monitoring","mono":"<ul><li>Viral load: at baseline and with modification of antiretroviral (ARV) treatment, at 2 to 8 weeks; then every 4 to 8 weeks until values are below the limit of detection (less than 200 copies\/mL), then every 3 to 4 months; monitoring may be extended to every 6 months for patients who are immunologically stable, adherent, and with suppressed viral loads for more than 2 years<\/li><li>CD4 cell counts: at baseline and with modification of ARV treatment, then every 3 to 6 months during the at least the first 2 years of treatment and if the CD4 counts are below 300 cells\/mm(3) or viremia develops; after 2 years monitoring may be extended to every 12 months for patients who are clinically stable with suppressed viral loads<\/li><li>Hepatitis B screening: baseline and with modification of ARV treatment; may repeat screening if hepatitis B surface antigen or antibody are negative at baseline.<\/li><li>ALT, AST, and total bilirubin; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>Basic chemistry, including serum sodium, potassium, bicarbonate, chloride, BUN, and creatinine; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 3 to 6 months<\/li><li>CBC with a differential; at baseline and with modification of ARV treatment, then every 3 to 6 months<\/li><li>Fasting blood glucose or HbA1c; at baseline and with modification of ARV treatment, then every 3 to 6 months with abnormal values or 12 months with normal values<\/li><li>Fasting lipid profile; at baseline and with modification of ARV treatment, at 2 to 8 weeks, then every 6 to 12 months<\/li><li>Urinalysis; at baseline or modification of ARV treatment, then annually<\/li><li>Signs or symptoms of hepatoxicity; during therapy in patients with underlying hepatic disease (eg, infection with hepatitis B or C virus)<\/li><\/ul>"},"11":{"id":"930754-s-11","title":"How Supplied","mono":"<b>Tivicay<\/b><br\/>Oral Tablet: 50 MG<br\/>"},"13":{"id":"930754-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex using a latex condom. Drug does not prevent disease transmission.<\/li><li>Side effects may include insomnia, headaches, or redistribution or accumulation of body fat.<\/li><li>Instruct patient to report rash and to seek immediate medical help if their rash is accompanied by any of the following symptoms of hypersensitivity: fever; general ill feeling; extreme tiredness; muscle or joint aches; blisters or peeling of the skin; oral blisters or lesions; eye inflammation; facial swelling; swelling of the eyes; difficulty  breathing; and\/or symptoms of liver problems (eg, yellowing of the skin or whites of the eyes, dark or tea-colored urine, pale-colored stools, nausea, vomiting, loss of appetite, or pain, aching, or sensitivity on the right side below the ribs).<\/li><li>Advise patient to immediately report symptoms of infection.<\/li><li>Instruct patient to take drug 2 hours before or 6 hours after taking any antacids or laxatives that contain aluminum, magnesium, or sucralfate; iron or calcium supplements, including multivitamins; or buffered medications.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}